Cardiologists, ED specialists to discuss value of NT-proBNP, Troponin in diagnosis, therapy management of heart failure patients

Four experts in cardiology and emergency services will share their experiences with these cardiac biomarkers and discuss why they can literally be the difference between life and death

Given the need for speedy and accurate diagnosis of heart failure patients in emergency situations, Radiometer Medical in association with Express Healthcare invites you to a live panel discussion on ‘Value of NT-proBNP and Troponin in diagnosis & therapy management of heart failure patients’ on WORLD HEART DAY, Tuesday, September 29, from 2-3 PM.

Four experts in cardiology and emergency services will share their experiences with these cardiac biomarkers and discuss why they can literally be the difference between life and death.

Every year, September 29 is celebrated as World Heart Day. Cardiovascular Disorders (CVD), including heart disease and stroke, is the world’s leading cause of death claiming 17.9 million lives each year¹. And this year, with an unheard novel corona virus resulting in potentially severe consequences, taking care of the heart has become more important than ever. Many trends emerged over the course of time and one such is that COVID-19 posed a particular risk to patients with underlying issues such as heart disease, which is already the leading cause of death in the planet¹.

Heart failure is a chronic life-threatening disorder with acute decompensated phases. About 26 million adults worldwide are living with heart failure (HF), leading some to describe it as a global pandemic.² Heart failure is a leading cause of hospitalisation among adults and the elderly. The prevalence of heart failure worldwide is growing due to a variety of factors, such as the aging of the population and the increase of patients being diagnosed with heart failure.³ The condition of chronic heart failure progresses rapidly.

Diagnosing heart failure (HF) in patients presenting in the Emergency Department (ED) is difficult. Quick and correct differential diagnosis of this condition is critical as late or incorrect diagnosis delays initiation of appropriate treatment, increasing morbidity and mortality as well as treatment costs.⁴ Clinical assessment of symptoms and signs has limited sensitivity and specificity. Often, patients are elderly with comorbidity, symptoms may be mild, and echocardiography may not be universally available.

In such circumstances, cardiac biomarkers viz., NT-proBNP and Troponin tests in the ED aids in the correct identification and selecting the patient who need an echocardiographic study. In addition, it results in an optimisation of healthcare resources for patients at risk of adverse events allowing for intensified care⁴.

In this panel discussion, you will learn from experts in Cardiology and Emergency Services about current trends in diagnosis and therapy management in acute heart failure patients. The natriuretic peptides viz., NT-proBNP and BNP are known to play an important role in the diagnosis of dyspneic patients presented to EDs. Learn more on the value these natriuretic peptides hold, if these can lower the diagnosis uncertainty and lower the rate of unnecessary imaging and how they can be used for risk stratification. Also understand if they can be used in therapy management of sacubitril/valsartan, with patients undergoing therapy and why NT-proBNP is more suitable to use in such cases

Don’t miss registering today for the panel discussion for answers to these questions and more. Link to register: https://expresshealthcare.in/lp/webinar/value-of-nt-probnp-and-troponin.php?utm_source=radiometer

References:

1. https://www.world-heart-federation.org/world-heart-day/about-whd/
2. Ambrosy PA et al., JACC Vol. 63, no 12, 2014:1123–1133
3. Anh L. Bui, Tamara B. Horwich, and Gregg C. Fonarow, Epidemiology and risk profile of heart failure
4. https://acutecaretesting.org/en/articles/nt-probnp-for-heart-failure-diagnosis-in-primary-care